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ABSTRACT
Background: This prospective, open-label, non-
comparative, multicentre, long-term phase IV
study is examining the efficacy and safety of
somatropin [recombinant human growth
hormone (rhGH)] in short children born small
for gestational age (SGA) and its impact on the
incidence of diabetes. This report is the first
interim analysis of patients who have
completed 1 year of treatment.
Methods: A total of 278 pre-pubertal patients
were enrolled. Key eligibility criteria included
height standard deviation score (HSDS) \-2.5;
parental adjusted SDS\-1; birth weight and/or
length \-2 SD and failure to show catch-up
growth by C4 years of age. Patients were treated
with rhGH 0.035 mg/kg/day. The primary
objective was to evaluate the long-term effect
of rhGH on carbohydrate metabolism
[including fasting glucose, stimulated glucose
(2-h oral glucose tolerance test, OGTT) and
glycated haemoglobin (HbA1c)]. Secondary
objectives included evaluation of height
parameters [body height, HSDS, height
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velocity (HV), HVSDS]; insulin-like growth
factor 1 (IGF-I) and insulin-like growth factor-
binding protein 3 (IGFBP-3) serum levels during
treatment; and incidence and severity of
adverse events (AEs).
Results: None of the children developed
diabetes mellitus within the first year of
treatment. Mean levels of fasting glucose,
HbA1c and 2-h OGTT values remained stable
during the study period. Treatment with rhGH
was effective, as documented by all height
parameters. Mean HSDS improved from -3.39
at baseline to -2.57 at Year 1. Mean HV
increased markedly from 4.25 cm/year at
baseline to 8.99 cm/year during the first year.
Similarly, mean peak-centred HVSDS increased
from -2.13 at baseline to ?4.16 at Year 1. Mean
IGF-I SDS and IGFBP-3 SDS also increased
within the first year (by ?1.80 and ?0.41,
respectively). 13 patients (4.7%) did not
respond adequately to treatment (HVSDS \1);
they were withdrawn from the study. In total,
192 children (69.3%) experienced treatment-
emergent AEs; most (98.7%) were mild-to-
moderate, and the majority (96.5%) were
unrelated to study treatment.
Conclusion: This interim analysis shows that
short children born SGA can be effectively and
safely treated with rhGHand that rhGHtreatment
has no major impact oncarbohydrate metabolism
after the first year of treatment.
Keywords: Endocrinology; Omnitrope;
Recombinant human growth hormone; Small
for gestational age; Somatropin
INTRODUCTION
Infants with birth size small for gestational age
(SGA) can represent up to 10% of all live births
each year, depending on the definition used
[1]. While the majority of children born SGA
achieve appropriate catch-up growth by the
age of 2–3 years, approximately one in ten does
not, and these children are at increased risk of
childhood and adult short stature [2, 3].
Therefore, current guidelines recommend
early intervention [in the form of treatment
with recombinant human growth hormone
(rhGH), somatropin] for short children born
SGA who still show severe growth retardation
by 2–4 years of age [4]. In addition,
epidemiological evidence suggests that
children born SGA may also be at an
increased risk of insulin resistance and type 2
diabetes in later life [5, 6] and there is also an
association between low birth weight and later
health problems, such as heart disease and
stroke [4].
The efficacy and safety of GH therapy for
children born SGA has been demonstrated in
several studies [7–10]. However, given that GH
therapy can induce transient insulin resistance
in children [11], concerns exist over its
diabetogenic potential in individuals
inherently predisposed to metabolic
abnormalities, such as children born SGA.
Currently, there is a paucity of long-term
data on the use of rhGH therapy in short
children born SGA, as well as its impact on
diabetes. This ongoing, long-term, phase IV
multicentre study with rhGH (Omnitrope,
Sandoz GmbH, Kundl, Austria) is the largest
prospective clinical study of GH therapy in SGA
patients conducted to date. The safety and
efficacy of rhGH therapy will be thoroughly
evaluated, especially in terms of its diabetogenic
potential and its ability to stimulate growth.
Here we report data from the first interim
analysis of patients who have completed
1 year of treatment.
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METHODS
Study Design and Patients
This is a prospective, open-label, non-
comparative, multicentre, phase IV study in
children born SGA.
Eligible patients are pre-pubertal (Tanner
stage I) children born SGA with growth
disturbances defined as current height
standard deviation score (HSDS) \-2.5 (and
parental adjusted SDS \-1) for chronological
age and sex according to country-specific
references. Additional inclusion criteria are
birth weight and/or length \-2 SD for
gestational age; failure of catch-up growth
[height velocity (HV) SDS \0 during the last
year] by 4 years of age or later; height records
available between 18 months and 6 months
before the start of GH treatment.
Key exclusion criteria include onset of
puberty; closed epiphyses; diabetes mellitus
type 1 or 2; fasting blood glucose[100 mg/dL or
[5.6 mmol/L; abnormal 2-h oral glucose
tolerance test (OGTT, [140 mg/dL or [7.8
mmol/L); acute critical illness; previous
treatment with any GH preparation; treatment
with antidiabetic medication (e.g. metformin,
insulin); known insulin-like growth factor 1
(IGF-I) level above ?2 SD for gender and age;
and drug, substance, or alcohol abuse. Patients
were also excluded if they had any other disease,
genetic disorder or treatment known to be
associated with growth retardation, e.g. Turner
or Noonan syndrome, Laron syndrome, Russell–
Silver syndrome, Prader–Willi syndrome, skeletal
dysplasias, chronic renal failure, cystic fibrosis,
heart and liver diseases, malabsorption (coeliac
disease), malnutrition, or were receiving
radiation therapy of the head or spinal cord.
The study protocol and all amendments were
reviewed by the Independent Ethics Committee
or Institutional Review Board for each centre.
All procedures followed were conducted in
accordance with the Declaration of Helsinki of
1975, as revised in 2000 and 2008, and in
compliance with Good Clinical Practice, with
written informed consent obtained from the
parent(s) or legal guardian(s) of all participants.
Patients could voluntarily withdraw from the
study at any time.
Study Treatment
Patients were treated with rhGH 0.035 mg/kg/
day by subcutaneous injection in the evening.
The investigator trained the patients (or their
legal guardians) to administer the study drug as
prescribed. Doses had to be adjusted at each
study visit within defined limits. Concomitant
medications could be given at the investigator’s
discretion.
Study Objectives
The primary objective is to evaluate the long-
term effect of rhGH treatment on the
development of diabetes mellitus in short
children born SGA. In this paper we present
data after 1-year of follow-up.
Secondary objectives include an evaluation
of efficacy through changes in height
parameters; measurement of rhGH-induced
serum markers IGF-I and insulin-like growth
factor-binding protein 3 (IGFBP-3); incidence
and severity of adverse events (AEs) and
detection of anti-rhGH antibodies during
treatment.
Timing of Assessments
Height was measured in cm and HV calculated.
HSDS and HVSDS (based on country-specific
reference tables) were assessed at baseline and at
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3-month intervals throughout the first year. To
determine bone age, X-rays of the left hand and
wrist were obtained at baseline and once-yearly
thereafter.
IGF-I and IGFBP-3 were measured by a
central laboratory at screening and at 3, 6, 9
and 12 months thereafter. IGF-I and IGFBP-3
serum levels were categorised as low (\-2 SD),
normal, or high ([?2 SD), compared with the
normal ranges, and serum level changes from
baseline to Year 1 were analysed.
Fasting plasma glucose, 2-h OGTT, HbA1c and
insulin levels were measured at baseline,
6 months, 12 months and annually thereafter.
Homeostatic model assessment (HOMA) score
(marker of insulin resistance) and the quantitative
insulin sensitivity check index (QUICKI) were
calculated as previously described [12–14].
All AEs were recorded at each visit and their
incidence is reported using the Medical
Dictionary for Regulatory Activities (MedDRA)
preferred terms, version 14.0 or higher [15].
Treatment Failure
Treatment was discontinued after 1 year if
HVSDS \1 (i.e. the patient is classed as a non-
responder). All responders will continue
treatment until final height is reached
[HV \2 cm/year and/or confirmed bone age of
[14 years (girls) or [16 years (boys)]. In cases
where the investigator does not agree with the
outcome of the central assessment of treatment
failure (based on height measurement), the
treatment response is reassessed by an
independent bone-age reader.
Like all patients that are treated within this
study, patients classed as ‘‘non-responders’’ are
also offered the option to participate in a
10-year follow-up safety study (EP00-402;
NCT01491854). During this 10-year follow-up,
all patients included will be analysed for safety,
with particular emphasis on the development of
diabetes after the end of rhGH therapy.
Additional Safety Assessments
Physical examinations and vital signs were
performed at each scheduled visit.
Haematology, blood chemistry, thyroid
function tests [free thyroxine (FT4) and thyroid
stimulating hormone (TSH) levels], lipids and
urinalysis were assessed at baseline, 6 months
and Year 1. Patients with hypothyroidism, who
were untreated, inadequately treated or had been
treated for less than 3 months, were excluded
from the study.
Anti-GH antibodies were measured centrally
using a previously validated radio-binding assay
for non-neutralizing anti-GH antibodies, using
radiolabelled (125I) rhGH as a ligand. The results
are reported in index units calculated from a
normal pool. The cut-off value (high reference
range) for determining whether patients had
developed anti-GH antibodies was 1.76.
Statistical Analyses and Patient
Populations
The current analysis includes data from baseline
up to the 1-year visit. Further analyses are
planned for 2013 (2 year-visit) and 2021 (end
of treatment).
All analyses were performed using SAS
Version 9.1.3 or later (SAS Institute Inc, Cary,
NC, USA). The probability for developing
diabetes mellitus was calculated using the
Poisson distribution. HOMA, QUICKI, IGF-I,
IGFBP-3 and standard deviation scores (SDS)
for IGF-I and IGFBP-3 were evaluated using
descriptive statistics. Bone age (BA) and height
age (HA) were derived during the analysis. Mean
values and 95% confidence intervals (CI) were
also calculated for males and females. Paired
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t tests were used to calculate p values, with
statistical significance defined as p\0.05. The
intent-to-treat (ITT) population comprised all
subjects enrolled in the study who received at
least one dose of study medication. The safety
population consisted of all patients who
received at least one dose of study medication




A total of 32 centres have recruited and treated
patients: 14 centres in Poland, 6 in Romania, 5
in Hungary, 3 in Czech Republic, 2 in Germany,
1 in Belgium and 1 in Georgia.
The study commenced in February 2008. At
the time of database lock for this first interim
analysis (19 October 2011) 333 patients had
been screened, and 278 were enrolled into the
study and received study medication. Of these,
277 had at least one post-baseline visit and 269
had completed their first year of treatment. The
majority of patients were compliant with
treatment (99.3% at the 12-month visit).
Patient disposition is shown in Fig. 1.
Patient demographics and baseline
characteristics are shown in Table 1. Slightly
more patients were males (53.2%) than females,
mean age on admission to the study was
Fig. 1 Patient disposition
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7.4 years (range 4–14 years) and almost all
patients (98.9%) were of Caucasian ethnicity.
Birth history was similar for boys and girls.
Impact of rhGH on Diabetes (Primary
Endpoint)
The development of diabetes was evaluated by
the fasting plasma glucose and 2-h OGTT.
According to these assays, none of the children
developed diabetes mellitus within the first year
of treatment, since no fasting glucose or 2-h
OGTT value exceeded the pre-defined upper
limits ([126 or [200 mg/dL, respectively).
Similarly, mean levels of HbA1c did not increase
during the first year of treatment (5.3 at baseline
and 5.4 at Year 1) (Table 2). Transient increases
in fasting glucose occurred in 23 patients (8.3%),
while 15 patients (5.1%) experienced transient
impaired glucose tolerance.
Mean (±SD) HOMA score increased slightly
from baseline (1.01 ± 1.03) to Year 1
(1.57 ± 1.11), while the QUICKI score
decreased slightly from baseline (0.42 ± 0.10)
to Year 1 (0.38 ± 0.05). These changes were
considered by the investigators as not clinically
significant. Shift table analyses of glucose
parameters indicated that the majority of
patients had normal values at baseline, which
remained within this range at Year 1 (data not
shown). Overall, there were no significant
abnormalities in glucose parameters during the
first year of treatment.
Impact of rhGH Treatment on BMI
Mean (SD) BMI SDS at baseline was -1.54
(1.36). This changed on slightly, to -1.64
(1.25), at Year 1.
Table 1 Patient demographics and baseline characteristics
Characteristics Male (n5 148) Female (n5 130) Total (n5 278)
Gender, n (%) 148 (53.2) 130 (46.8) 278 (100)
Mean age (SD), years 7.7 (2.7) 7.0 (2.6) 7.4 (2.7)
Mean height (SD), cm 112.4 (14.2) 108.6 (14.0) 110.6 (14.2)
Mean height SDS (SD) -3.38 (0.77) -3.40 (0.78) -3.39 (0.78)
Mean height velocity (SD), cm/year 4.09 (1.33) 4.43 (1.26) 4.25 (1.30)
Peak centred height velocity SDS (SD) -2.29 (1.9) -1.96 (1.5) -2.13 (1.7)
Mean weight (SD), kg 19.3 (6.3) 17.0 (5.3) 18.3 (6.0)
Caucasian ethnicity, n (%) 146 (98.6) 129 (99.2) 275 (98.9)
Mean birth weight (SD), g 2,073.2 (491.9) 2,044.0 (458.0) 2,059.6 (475.7)
Mean birth weight SDS (SD) -3.2 (1.3) -2.9 (1.1) -3.0 (1.2)
Mean birth length (SD), cm 46.3 (3.7) 46.5 (3.8) 46.4 (3.7)
Mean birth length SDS (SD) -2.1 (1.6) -1.6 (1.3) -1.8 (1.6)
Gestational age (SD), weeks 38.4 (2.5) 38.5 (2.5) 38.5 (2.5)
SD standard deviation, SDS standard deviation score
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Pubertal Status
Only pre-pubertal children were enrolled in the
study (Table 1) and their pubertal status was
monitored throughout. The vast majority of
children remained pre-pubertal (Tanner stage I)
from baseline to Year 1 [n = 216 (80.3%)]. No
children reached Tanner stage V, but there were
a few that reached Tanner stage II [n = 41
(15.2%)], III [n = 10 (3.7%)], or IV [n = 2
(0.7%)].
Additional Safety Assessments
A total of 649 treatment-emergent AEs were
reported in 192 children (69.3%); most (98.7%)
were mild-to-moderate in intensity and the
majority (96.5%) were judged to be unrelated
to study treatment.
The most frequently occurring AEs (by
MedDRA preferred term) were nasopharyngitis
(n = 53, 19.1%), pharyngitis (n = 51, 18.4%),
upper respiratory tract infections (n = 25, 9%)
and bronchitis (n = 23, 8.3%) (Table 3). AEs
with a suspected relationship to study drug
were rare; the most frequently reported were
hypothyroidism (7 patients, 2.5%) and
headache (3 patients, 1.1%).
Serious AEs were reported in 19 patients
(6.9%), with only one suspected to be
treatment-related (severe headache). No
malignancies have been observed in the study
to date, no patients have died during the first
year of treatment and only one patient
discontinued from the study due to a non-
serious AE (crying, aggressiveness and refusing
to take injections), which was considered
unrelated to the study drug.
In total, 17 children had a positive anti-hGH
antibody titre at one time point during the
study. The number of patients with anti-hGH
antibodies appeared to increase slightly over
time but remained at a low level, with only
seven patients (2.9%) testing positive at the
1-year visit.
Mean (SD) FT4 levels changed significantly
(p\0.0001) from baseline [16.42 (3.02) pmol/L,
n = 268] to Year 1 [15.27 (2.78) pmol/L,
n = 263]. TSH levels remained constant
throughout the first year of treatment
[baseline 2.84 (1.32) mU/L, n = 271; Year 1:
2.86 (1.42) mU/L, n = 265].
Table 2 Summary of glucose metabolism data
Parameter Visit N Mean SD Range Mean change from
baseline to Year 1
2-hour OGTT (mmol/L) Baseline 276 5.28 1.29 1.5–7.8 0.15 (n = 268)
Year 1 269 5.43 1.27 2.6–9.6 p = 0.14
Fasting glucose (mmol/L) Baseline 273 4.55 0.61 2.2–5.6 0.10 (n = 265)
Year 1 269 4.65 0.56 3.0–6.2 p = 0.01
Fasting insulin (pmol/L) Baseline 265 35.65 34.69 0.7–431.2 17.22 (n = 256)
Year 1 268 53.68 35.93 7.2–209.9 p\0.0001
HbA1c (%) Baseline 266 5.29 0.50 2.8–6.4 0.07 (n = 252)
Year 1 262 5.37 0.51 2.8–6.5 p = 0.005
HbA1c glycated haemoglobin, OGTT oral glucose tolerance test, SD standard deviation
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There were no clinically significant findings
in haematological parameters, blood chemistry,
urinalysis, or vital signs.
Efficacy Assessments (Secondary
Endpoints)
Body height increased steadily throughout the
treatment period; mean changes from baseline
were slightly greater in girls (9.29 cm) than in
boys (8.90 cm). Likewise, mean HSDS showed a
continuous increase and improved by 0.81
overall (p\0.0001) (Fig. 2). While this reflects
a net improvement of height, the values
achieved indicate that the mean height of the
study population was still shorter than average
after 1 year of treatment.
Mean HV increased markedly during the first
3 months of treatment (10.72 cm/year compared
with 4.25 cm/year at baseline; p\0.0001) and
then decreased slightly but remained higher
than at baseline (8.99 cm/year after 1 year;
p\0.0001) (Fig. 3a). There was no apparent
difference between boys and girls in terms of
Table 3 Incidence of AEs ([2%) by MedDRA preferred term and intensity
MedDRA preferred term Intensity Total
Mild Moderate Severe
Nasopharyngitis 52 (18.8%) 2 (0.7%) 0 53 (19.1%)
Pharyngitis 38 (13.7%) 14 (5.1%) 0 51 (18.4%)
Upper respiratory tract infection 21 (7.6%) 5 (1.8%) 0 25 (9.0%)
Bronchitis 20 (7.2%) 2 (0.7%) 1 (0.4%) 23 (8.3%)
Tonsillitis 10 (3.6%) 3 (1.1%) 0 13 (4.7%)
Headache 9 (3.2%) 2 (0.7%) 2 (0.7%) 12 (4.3%)
Hypothyroidism 9 (3.2%) 1 (0.4%) 0 10 (3.6%)
Pyrexia 10 (3.6%) 0 0 10 (3.6%)
Cough 9 (3.2%) 1 (0.4%) 0 10 (3.6%)
Rhinitis 7 (2.5%) 2 (0.7%) 1 (0.4%) 10 (3.6%)
Urinary tract infection 9 (3.2%) 1 (0.4%) 0 10 (3.6%)
Ear infection 9 (3.2%) 0 0 9 (3.2%)
Diarrhoea 7 (2.5%) 2 (0.7%) 0 9 (3.2%)
Otitis media 6 (2.2%) 3 (1.1%) 0 8 (2.9%)
Varicella 8 (2.9%) 0 0 8 (2.9%)
Vomiting 7 (2.5%) 0 0 7 (2.5%)
Abdominal pain 6 (2.2%) 1 (0.4%) 0 7 (2.5%)
Viral infection 6 (2.2%) 0 0 6 (2.2%)
Rhinorrhoea 6 (2.2%) 0 0 6 (2.2%)
Lymphadenopathy 6 (2.2%) 0 0 6 (2.2%)
AE adverse event, MedDRA medical dictionary for regulatory activities
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mean change in HV (4.69 versus 4.79,
respectively). Similarly, mean peak-centred
HVSDS initially increased markedly from a
negative value at baseline (-2.13), reaching
6.31 after 3 months (p\0.0001) and remaining
high (4.16) by Year 1 (p\0.0001) (Fig. 3b).
A small number of children (13/278, 4.7%)
did not respond adequately to treatment after
the first year (HVSDS \1) and were withdrawn
from treatment.
IGF-I and IGFBP-3
IGF-I and IGFBP-3 were measured as surrogate
indicators of treatment efficacy. Mean IGF-I SDS
showed a steady increase from baseline (-1.08)
to Year 1 (?0.72) (p\0.0001) (Fig. 4a). Shifts in
IGF-I serum level categories indicated that at
baseline most patients had normal (n = 208;
77.3%) or low (\-2 SD) IGF-I levels (n = 44;
16.4%). At 1 year, this distribution shifted, so
that only two patients had low levels and the
majority had normal (n = 202; 75.1%) or high
(n = 40; 14.9%) IGF-I levels.
Mean IGFBP-3 SDS was ?0.11 at baseline,
increasing to ?0.52 at Year 1 (p\0.0001)
(Fig. 4b). Shifts in IGFBP-3 serum level
categories showed that the majority of patients
(n = 247; 91.8%) had normal IGFBP-3 levels at
baseline. At Year 1, this distribution was
essentially unchanged, with 232 patients
(86.2%) having normal levels of IGFBP-3.
Molar IGF-I/IGFBP-3 ratios increased
throughout the first year, and had almost
doubled by Year 1, compared with baseline
[0.23 versus 0.12, respectively; mean difference
0.11 (p\0.0001)].
DISCUSSION
Short children born SGA are predisposed to
metabolic abnormalities, with the pattern of
carbohydrate metabolism typically one of
compensated insulin resistance without obvious
Fig. 2 Mean HSDS (±SD) for children born SGA during
1 year of treatment with recombinant human growth
hormone (rhGH)
Fig. 3 a Mean HV (±SD) and b mean HVSDS (±SD) for children born SGA during 1 year of treatment with
recombinant human growth hormone (rhGH)
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abnormality of fasting or post-prandial glucose
[16]. GH treatment, with its insulin antagonistic
action, could potentially increase the risk of type 2
diabetes in this patient group [11].
The main objective of the present study is to
evaluate the effect of rhGH treatment on the
development of diabetes in short children born
SGA. In this first interim analysis, no patients
developed diabetes during the first year of
treatment. Glucose levels (fasting plasma
glucose), glucose tolerance (OGTT) and HbA1c
remained stable over the first year of treatment,
while fasting insulin increased slightly. These
findings are consistent with the concept that,
while GH treatment may increase insulin
resistance in children born SGA, there is a
compensatory hyperinsulinaemia that
maintains normal glucose regulation during
treatment [17].
These 1-year interim data are also consistent
with data from a study of glucose tolerance and
insulin sensitivity during GH treatment of 84
children born SGA, which reported that while a
reduction in insulin sensitivity was observed,
glucose tolerance remained normal [10]. In
addition, other recent studies in children born
SGA reported that any rhGH-induced changes
in insulin levels reverted to normal upon
treatment discontinuation, while fasting blood
glucose remained within normal limits during a
2-year treatment period [18].
The incidence of anti-rhGH antibodies during
the first year of treatment was low. This is
consistent with findings from other longer-term
studies examining the efficacy and safety of
rhGH in children with GH deficiency, which
have also reported low levels of anti-rhGH
antibodies after 4–7 years of treatment [19, 20].
The incidence of treatment-related
hypothyroidism (2.5%) and headache (1.1%)
reported in this study was comparable to other
clinical trials. Moreover, it is generally
recognised that rhGH therapy has a good
safety profile in children born SGA [1].
The increase in growth velocity and height
gain during the first year of GH treatment in the
present study was excellent and compares
favourably with data reported in several other
studies of SGA children treated with various































BBaseline to Year 1: Δ+1.80 (p<0.0001)
Baseline to Year 1: 
Δ+0.41 (p<0.0001)
Fig. 4 Mean (±SD) IGF-I SDS (a) and mean (±SD) IGFBP-3 SDS (b) during the ﬁrst year of treatment with
recombinant human growth hormone (rhGH) in children born SGA
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When treating children born SGA, it is
important to define an acceptable level of
response to GH therapy so that decisions can
be made promptly to discontinue treatment in
the event of treatment failure. A change in HSDS
\0.2 in a child aged 5 years has been proposed
as a clinically insignificant response [21].
However, consensus guidelines consider a
positive growth response within the first year
of GH treatment as a change in HVSDS of more
than ?0.5 [4]. In the present study, this was
achieved in all patients classified as responders,
since the study protocol applied a stricter
definition, i.e. HVSDS had to be at least ?1
after the first year of treatment for patients to be
eligible to continue with therapy.
An obvious limitation of the study is the lack
of an (untreated) control group. Another
potential limitation is that most patients were
older than 4 years at initiation of rhGH therapy.
However, the statistically significant treatment
benefits that were observed in the majority of
patients across all height parameters indicate
that this is a GH-responsive population. The few
non-responsive patients were withdrawn from
the study at the 1-year visit, as stipulated by the
approved study protocol.
CONCLUSIONS
The results of this first interim analysis show
that short children born SGA can be effectively
and safely treated with rhGH (Omnitrope).
Further scheduled interim analyses and the final
analysis of this study, which is the largest
prospective clinical study of rhGH treatment
in SGA patients conducted to date, will enable a
more comprehensive and conclusive assessment
of long-term safety and efficacy in this patient
population.
ACKNOWLEDGMENTS
This study was funded by Sandoz
Biopharmaceuticals.
Sponsorship and article processing charges for
this study were funded by Sandoz
Biopharmaceuticals. Medical writing assistance
in the preparation of this paper was provided by
Tony Reardon of Spirit Medical
Communications Ltd and funded by Sandoz
International GmbH.
All authors had full access to all of the data in
this study and take complete responsibility for
the integrity of the data and accuracy of the
data analysis.
All named authors meet the ICMJE criteria for
authorship for this manuscript, take
responsibility for the integrity of the work as a
whole and have given final approval to the
version to be published.
Conflict of interest. H.P. Schwarz has
received fees from Sandoz Biopharmaceuticals/
Hexal AG as International Co-ordinating
Investigator for the EP00-401 and EP00-402
studies.
J. Khan-Boluki is an employee of Sandoz
Biopharmaceuticals.
E. Schuck is an employee of Sandoz
Biopharmaceuticals.
D. Birkholz-Walerzak, M. Szalecki, M.
Walczak, C. Galesanu and D.Metreveli declare
no conflicts of interest.
Compliance with ethics guidelines. The
study protocol and all amendments were
reviewed by the Independent Ethics
Committee or Institutional Review Board for
each centre. All procedures followed were
conducted in accordance with the Declaration
of Helsinki of 1975, as revised in 2000 and 2008
Biol Ther (2014) 4:1–13 11
and in compliance with Good Clinical Practice,
with written informed consent obtained from
the parent(s) or legal guardian(s) of all
participants. Patients could voluntarily
withdraw from the study at any time.
Open Access. This article is distributed
under the terms of the Creative Commons
Attribution Noncommercial License which
permits any noncommercial use, distribution,
and reproduction in any medium, provided the
original author(s) and the source are credited.
REFERENCES
1. Saenger P, Czernichow P, Hughes I, Reiter EO. Small
for gestational age: short stature and beyond.
Endocr Rev. 2007;28:219–51.
2. Lee PA, Chernausek SD, Hokken-Koelega AC, et al.
International Small for Gestational Age Advisory
Board consensus development conference
statement: management of short children born
small for gestational age. Pediatrics.
2003;111:1253–61.
3. Albertsson-Wikland K, Karlberg J. Postnatal growth
of children born small for gestational age. Acta
Paediatr Suppl. 1997;423:193–5.
4. Clayton PE, Cianfarani S, Czernichow P,
Johannsson G, Rapaport R, Rogol A. Management
of the child born small for gestational age through
to adulthood: a consensus statement of the
International Societies of Pediatric Endocrinology
and the Growth Hormone Research Society. J Clin
Endocrinol Metab. 2007;92:804–10.
5. Bhargava SK, Sachdev HS, Fall CH, et al. Relation of
serial changes in childhood body-mass index to
impaired glucose tolerance in young adulthood.
N Engl J Med. 2004;350:865–75.
6. Eriksson JG, Osmond C, Kajantie E, Forse´n TJ,
Barker DJ. Patterns of growth among children who
later develop type 2 diabetes or its risk factors.
Diabetologia. 2006;49:2853–8.
7. Sas T, De Waal W, Muler P, et al. Growth hormone
treatment in children with short stature born small
for gestational age: 5-year results of a randomized,
double-blind, dose-response trial. J Clin Endocrinol
Metab. 1999;84:3064–70.
8. Sas TC, Gerver WJ, De Bruin R, et al. Body
proportion during 6 years of GH treatment in
children with short stature born small for
gestational age participating in a randomised,
double-blind, dose-response trial. Clin Endocrinol
(Oxf). 2000;53:675–81.
9. Czernichow P. Growth hormone treatment strategy
for short children born small for gestational age.
Horm Res. 2004;62:137–40.
10. Cutfield WS, Lindberg A, Rapaport R, Wajnrajch
MP, Saenger P. Safety of growth hormone treatment
in children born small for gestational age: the US
trial and KIGS analysis. Horm Res. 2006;65(Suppl
3):153–9.
11. Delemarre EM, Rotteveel J, Delemarre-van der Waal
HA. Metabolic implications of GH treatment in
small for gestational age. Eur J Endocrinol.
2007;157:S47–50.
12. Matthews DR, Hosker JP, Rudenski AS, et al.
Homeostasis model assessment: insulin resistance
and beta-cell function from fasting plasma glucose
and insulin concentrations in man. Diabetologia.
1985;28:412–9.
13. Katz A, Nambi SS, Malther K, et al. Quantitative
insulin sensitivity check index: a simple, accurate
method for assessing insulin sensitivity in humans.
J Clin Endocrin Metab. 2000;85:2402–10.
14. World Health Organisation (WHO). Definition and
diagnosis of diabetes mellitus and intermediate




15. MedicalDictionary for RegulatoryActivities (MedDRA)
preferred terms, version 14.0 or higher. http://www.
meddra.org/how-to-use/support-documentation
(Accessed January 13, 2014).
16. Jung H, Rosilio M, Blum WF, Drop SL. Growth
hormone treatment for short stature in children
born small for gestational age. Adv Ther. 2008;25:
951–78.
17. Cutfield WS, Jackson WE, Jefferies C, et al. Reduced
insulin sensitivity during growth hormone therapy
for short children born small for gestational age.
J Pediatr. 2003;142:113–6.
18. Lebl J, Lebenthal Y, Kolouskova S, et al. Metabolic
impact of growth hormone treatment in short
children born small for gestational age. Horm Res
Paediatr. 2011;76:254–61.
19. Romer T, Saenger P, Peter F, et al. Seven years of
safety and efficacy of the recombinant human
12 Biol Ther (2014) 4:1–13
growth hormone Omnitrope in the treatment of
growth hormone deficient children: results of a
phase III study. Horm Res. 2009;72:359–69.
20. Lo´pez-Siguero J, Borra´s Pe´rez MV, Balser S, Khan-
Boluki J. Long-term safety and efficacy of the
recombinant human growth hormone
Omnitrope in the treatment of Spanish growth
hormone deficient children: results of a phase III
study. Adv Ther. 2011;28:879–93.
21. Omokanye A, Onyekpe I, Patel L, et al. Defining
criteria for poor responders to growth hormone
(GH) in short children born small for gestational
age (SGA). 37th meeting of the British Society for
Paediatric Endocrinology and Diabetes, Reading;
2009 (Endocrine Abstracts 23 P10).
Biol Ther (2014) 4:1–13 13
